Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Germany
/
Healthcare
Create a narrative
Stratec
XTRA:SBS Community
1
Narratives
written by author
0
Comments
on narratives written by author
2
Fair Values set
on narratives written by author
Create a narrative
Stratec
Popular
Undervalued
Overvalued
Stratec
WA
Analyst Price Target
Consensus Narrative from 6 Analysts
Efficiency Measures And Acquisitions Like Natech Will Boost Future Market Presence
Key Takeaways Efficiency measures and cost discipline initiatives could enhance net margins as market conditions stabilize. Strategic acquisitions and market recovery optimism are expected to drive future revenue growth, especially in immunoassay and immune hematology segments.
View narrative
€41.00
FV
26.6% undervalued
intrinsic discount
6.92%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
12 days ago
author updated this narrative
Your Valuation for
SBS
Stratec
Your Fair Value
€
Current Price
€30.10
0.9% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
338m
2015
2018
2021
2024
2025
2027
2030
Revenue €337.6m
Earnings €13.5m
Advanced
Set as Fair Value